|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.65 SEK | +0.58% |
|
+0.58% | +32.67% |
| 06-18 | Lipum AB Completes Multiple Dose Part of the Phase I Clinical Study | CI |
| 05-28 | Lipum AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Lipum AB (publ) is in the final stages of the clinical phase I study with SOL-116. In parallel, the company is preparing for the next step, a phase II study in rheumatoid arthritis.
| 1st Jan change | Capi. | |
|---|---|---|
| +32.67% | 17.34M | |
| +2.87% | 94.22B | |
| -4.08% | 37.76B | |
| -13.70% | 32.5B | |
| +73.38% | 27.75B | |
| -11.63% | 16.13B | |
| -0.62% | 14.19B | |
| -11.67% | 11.42B | |
| +190.36% | 11.06B | |
| -52.61% | 9.09B |
LIPUM AB 
